Company Filing History:
Years Active: 2008
Title: A Karl Malakian: Innovator in TNF Signaling Pathways
Introduction
A Karl Malakian, an inventive mind hailing from Boxborough, MA, has made significant strides in the field of biomedical research. With a focus on tumor necrosis factor (TNF) signaling pathways, his contributions have the potential to impact therapeutic strategies for various diseases.
Latest Patents
Malakian holds a notable patent titled "N-TRADD active site and uses thereof." This patent pertains to the three-dimensional solution structure of the N-terminal domain of TNFR-1 associated death domain protein, known as N-TRADD. The invention not only identifies a C-TRAF2 binding active site of N-TRADD but also outlines methods for utilizing these three-dimensional structures. These methods are aimed at designing and selecting potent and selective inhibitors of TNF signaling pathways, presenting a promising avenue for pharmaceutical development.
Career Highlights
Currently, Malakian is associated with Genetics Institute, Inc., a company known for its innovative approaches in the field of biotechnology. His role at Genetics Institute allows him to leverage his expertise in molecular structures to further advance research in TNF signaling mechanisms.
Collaborations
Throughout his career, Malakian has collaborated with esteemed colleagues such as Desiree H H Tsao and Jean-Baptiste Telliez. These partnerships have fostered an enriching environment for scientific discovery and innovation, promoting a collective effort to push the boundaries of current knowledge.
Conclusion
A Karl Malakian stands out as a key inventor in the realm of TNF signaling pathways, illuminating the path toward potential therapeutic breakthroughs. His dedication to understanding complex molecular interactions exemplifies the spirit of innovation, making him a valuable contributor to the ongoing fight against various diseases.